Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Bausch + Lomb Corporation ( (BLCO) ) is now available.
Bausch + Lomb has launched the enVista Aspire monofocal and toric intraocular lenses in the European Union following their CE Mark approval. These lenses feature advanced optics for a broader depth of focus, offering improved vision solutions for cataract patients, including those with astigmatism. This launch marks a strategic expansion of Bausch + Lomb’s intraocular lens portfolio in the European market, enhancing its competitive positioning and providing surgeons with new tools for modern vision correction needs.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company that focuses on helping people improve their vision for a better quality of life. The company is known for its comprehensive range of eye health products and services, particularly in the surgical and lens sectors.
YTD Price Performance: -1.33%
Average Trading Volume: 549,191
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.25B
For detailed information about BLCO stock, go to TipRanks’ Stock Analysis page.